Cullinan Therapeutics, Inc. financial data

Symbol
CGEM on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Main Street, Suite 1350, Cambridge, Massachusetts
Fiscal year end
December 31
Former names
Cullinan Oncology, Inc. (to 4/2/2024), Cullinan Management, Inc. (to 2/22/2021), Cullinan Oncology, LLC (to 1/6/2021)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.15K % +4.81%
Debt-to-equity 5.24 % +1.16%
Return On Equity -28.4 % -5.39%
Return On Assets -27 % -5.31%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 58M shares +35.7%
Common Stock, Shares, Outstanding 57.9M shares +35.4%
Entity Public Float 374M USD -0.4%
Common Stock, Value, Issued 6K USD +50%
Weighted Average Number of Shares Outstanding, Basic 55.1M shares +37.8%
Weighted Average Number of Shares Outstanding, Diluted 55.1M shares +37.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 136M USD +12.5%
General and Administrative Expense 47.7M USD +13%
Operating Income (Loss) -184M USD -12.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -169M USD -212%
Income Tax Expense (Benefit) -14.1M USD -134%
Net Income (Loss) Attributable to Parent -142M USD -0.28%
Earnings Per Share, Basic -3.06 USD/shares +10.3%
Earnings Per Share, Diluted -3.06 USD/shares +8.93%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 115M USD -18.9%
Other Assets, Current 3.9M USD
Assets, Current 678M USD +36%
Other Long-term Investments 15.5M USD -49.5%
Property, Plant and Equipment, Net 836K USD -27.8%
Operating Lease, Right-of-Use Asset 2.12M USD -39.4%
Other Assets, Noncurrent 460K USD +0.22%
Assets 681M USD +30.5%
Accounts Payable, Current 1.56M USD -37.6%
Accrued Liabilities, Current 20.7M USD +33.3%
Liabilities, Current 23.5M USD +19.3%
Operating Lease, Liability, Noncurrent 1.52M USD -44.4%
Liabilities 25M USD +11.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -476K USD +70.7%
Retained Earnings (Accumulated Deficit) -280M USD -103%
Stockholders' Equity Attributable to Parent 656M USD +31.4%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 656M USD +31.4%
Liabilities and Equity 681M USD +30.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -38.2M USD +25%
Net Cash Provided by (Used in) Financing Activities 1.09M USD -39.4%
Net Cash Provided by (Used in) Investing Activities 13M USD -14.7%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 57.9M shares +35.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 87.4M USD +86.8%
Deferred Tax Assets, Gross 88.3M USD +83.3%
Operating Lease, Liability 2.73M USD -37.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -141M USD -0.9%
Lessee, Operating Lease, Liability, to be Paid 3.05M USD -40%
Property, Plant and Equipment, Gross 1.34M USD +2.45%
Operating Lease, Liability, Current 1.22M USD -26.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 871K USD -40.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.46M USD -15.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 312K USD -54.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 872K USD -40.3%
Deferred Tax Assets, Operating Loss Carryforwards 14.4M USD +37.1%
Preferred Stock, Shares Issued 648K shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 872K USD
Preferred Stock, Shares Outstanding 648K shares 0%
Depreciation, Depletion and Amortization 76K USD +5.56%
Deferred Tax Assets, Net of Valuation Allowance 914K USD -34.8%
Share-based Payment Arrangement, Expense 34M USD +21.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%